KRAS and B-cell non-Hodgkin lymphoma: Finally, the relapsed tumors acquired a number of mutations in genes not typically altered in B-cell lymphomas such as KRAS, MAP2K2, PIK3R1, and PIK3R2, further supporting their loss of B-cell identity and suggesting that targeting PI3K and KRAS in such cases may prove therapeutically effective.